D. Ross Camidge, MD, PhD, and Eric K. Singhi, MD, preview the SCLC and NSCLC abstracts they are anticipating at the 2026 World Conference on Lung Cancer.
|Videos|February 25, 2012
2012 ONS Congress Coverage Coming Soon
Author(s)Onclive Team
Meeting coverage from the 2012 Oncology Nursing Society Congress held at the New Orleans Ernest N. Morial Convention Center, from May 3-6, 2012.
Advertisement
Meeting coverage from the 2012 Oncology Nursing Society Congress held at the New Orleans Ernest N. Morial Convention Center.
Check back May 3 - 6, 2012.
For registration and further information on the conference visit
Images From the 2011 ONS Congress
Advertisement
Related to this article
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Advertisement
Advertisement
Trending on OncLive
1
Durvalumab Plus Tarlatamab Boosts Survival as First-Line ES-SCLC Maintenance
2
Arlo-Cel Meets ORR End Point in BCMA-Pretreated, Quadruple-Class Exposed R/R Myeloma
3
Camidge and Singhi Highlight the Lung Cancer Abstracts to Watch at WCLC 2026
4
Frontline Mipletamig Triplet Drives Clinical Benefit in TP53-Mutated AML
5